Clinical pharmacology of axitinib.

@article{Chen2013ClinicalPO,
  title={Clinical pharmacology of axitinib.},
  author={Yin Chen and Michael A Tortorici and May Garrett and Brian Hee and Karen J. Klamerus and Yazdi K. Pithavala},
  journal={Clinical pharmacokinetics},
  year={2013},
  volume={52 9},
  pages={713-25}
}
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 that is approved in the US and several other countries for treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy. The recommended clinical starting dose of axitinib is 5 mg twice daily, taken with or without food. Dose increase (up to a maximum of 10 mg twice daily) or reduction is permitted based on individual tolerability… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…